

15th - 17th June 2017

Warsaw, Marriott Hotel

**4th GLOBAL FORUM
ON NICOTINE**

**Reducing Harm
Saving Lives**



#GFN17



SCIENCE PARTNERS



MEDIA PARTNERS



SUPPORTING ORGANISATIONS



LOCAL PARTNER

WELCOME TO DELEGATES

The conference team wishes you a warm welcome to this fourth Global Forum on Nicotine.

The theme for this year is **'Reducing Harm, Saving Lives'** and the programme will examine the rapidly developing science in relation to nicotine use and the changing landscape, including policy responses and the influence of different stakeholders in this.

Science continues to demonstrate the relative risks between smoking and other manifestly safer ways for people to use and enjoy nicotine. At the same time the political and regulatory minefield across the globe continues to create doubt and uncertainty about the future, for those who use new lower-risk products, as well as for the industry that produces them. This uncertainty itself risks our losing the opportunity for a massive public health gain, with the reduction in smoking related NCDs.

The programme brings together leading scientists, public health professionals and thinkers and consumers, with sessions designed to both inform and challenge participants to gain a better understanding of what the evidence is telling us. Presenters will address some of the issues that seem to polarise the debates about the scientific, commercial and regulatory issues that impact on the availability and safety of new nicotine products.

In addition to main agenda this year we have introduced a number of other elements to the conference. We are delighted that Dr Ethan Nadelmann will deliver the Michael Russell Memorial Oration, in which he will draw some parallels with his experience in the field of drug policy reform and what is currently happening with regard to nicotine regulation.

This year also sees the first International Symposium on Nicotine Technology (ISoNTech) where scientists will explain and demonstrate the work that is going into developing new, safer nicotine products. This will present the opportunity for detailed discussion and interrogation of the various technologies, enabling a better understanding of the science behind them.

One thing that endures is the aim and ethos of GFN, to create an open environment for discussion and debate, where evidence is the most important feature.

With participants including policy analysts, regulators and standards experts, academics and researchers, politicians, public health professionals, consumer advocates, and makers and distributors of alternative nicotine products, it provides a unique opportunity for exchange of views, learning and networking. Getting a shared understanding of the facts and the key players involved is an essential step in moving in effective directions.

We hope you find the conference interesting and of value. If you require any assistance during the event, please just ask at the registration desk and a member of the team will endeavour to help.

Information for GFN participants

The conference is funded by registrations and has not received any sponsorship from manufacturers, distributors or retailers of nicotine products including pharmaceutical, electronic cigarette and tobacco companies.

This is a multi-stakeholder event – participants include consumers, scientists, regulators, manufacturers and distributors, public health professionals, policy analysts and parliamentarians. Inevitably there will be a wide range of views expressed. We ask you to observe a basic ‘house rule’ that every speaker – whether from the platform, or the audience - deserves to be listened to with courtesy.

GFN 2017 Vaping Policy

GFN supports the rights of consumers and encourages their participation in the conference.

The law in Poland regarding vaping in public places has changed, as a result of their interpretation and implementation of the EU TPD, and in the light of this we have had to alter the vaping policy for the conference.

As a result of the new law vaping is not permitted in the public places. The conference venue is deemed to be a public place – this includes the corridors, exhibition area, media rooms and the rooms used for sessions – and thus vaping is not permitted. This is not the organisers’ decision, it is the policy of the management of the premises, compliant with Polish law.

We have negotiated with the hotel that one room can be designated a vaping room. This will be the Kometa Room, which is also the room set aside for use throughout the conference by INNCO. The room will also have a video relay of the conference proceedings from the main session room. Adjacent to the floor where the conference is taking place there is a terrace, which is covered and easily accessible for those who wish to use it, where vaping is also permitted.

We ask that all participants note and observe the policy during the course of the conference.

Filming and Photography

The conference welcomes commercial and non-commercial media coverage of the event, including film, photographic and audio recording. Filming and audio recording (excluding photography using small equipment such as mobile phones) in the session rooms is by permission of the organisers and should be done in an unobtrusive manner that does not impede the proceedings for participants. Unless otherwise agreed in writing, copyright in all images and recordings in the session rooms becomes joint copyright of the person, or organisation making the recording and the conference organisers. No film, images, or audio-recordings taken anywhere in the conference venue may be used in any commercial advertisement without the agreement of the organisers and those who appear in such media.

Michael Russell Memorial Oration 2017: delivered by Ethan Nadelmann

The Michael Russell Oration has been established as an annual event, delivered to honour the work and memory of **Professor Michael Russell**, one of the pioneers in the study of smoking behaviour, clinical interventions and public policy action, who died in 2009.



Michael Russell, a psychiatrist and research scientist, was a pioneer in the study of tobacco dependence and the development of treatments to help smokers quit. The enduring impact of his work is likely to place him among the foremost clinical public health scientists of the twentieth century.

He was born in Cape Town, South Africa, and whilst working in London at the Institute of Psychiatry between 1969 and 1998, he conducted a number of highly original studies that revolutionised our understanding of both the pharmacological and psychological basis of tobacco smoking. For public health the interventions and treatments he developed have had an enormous impact throughout the world, in reducing the morbidity and mortality caused by tobacco. In the UK his work formed much of the evidence base that inspired the new NHS Stop Smoking services, launched in the year after his retirement. He argued that while the tobacco industry remained free to market cigarettes, millions of lives would be prematurely ended, especially in the growing markets in developing countries, before sufficient numbers of smokers could quit. Based on the knowledge that pure nicotine carries little health risk, but is the main reason why people smoke, he advocated the development and promotion of safer nicotine products to the exclusion of cigarettes, to reduce the majority of harm caused by ingesting the non-nicotine toxins in burning tobacco. Michael Russell is the person who did most to lay the foundations for tobacco harm reduction that drives much research in the field today.

'Drug control and tobacco control: parallels, reform and advocacy' delivered by Ethan Nadelmann



Ethan Nadelmann is the founder and former executive director of the Drug Policy Alliance, the leading organization in the United States promoting alternatives to the war on drugs. Nadelmann received his B.A., J.D., and Ph.D. in Political Science from Harvard as well as a Masters' degree in International Relations from the London School of Economics, and taught at Princeton University for seven years. He has authored two books – *Cops Across Borders* and (with Peter Andreas) *Policing The Globe* – and his writings have appeared in most major media outlets in the U.S. as well as top academic journals, policy journals and political publications. He is interviewed frequently by media, including *The Colbert Report*, *The O'Reilly Factor*, *Real Time with Bill Maher*, and news programs on all the major U.S. networks as well as dozens of networks elsewhere.

Nadelmann and his colleagues have played pivotal roles in most of the major drug policy reform ballot initiative campaigns in the United States on issues ranging from medical marijuana and marijuana legalization to prison reform, drug treatment and reform of asset forfeiture laws. They also have reformed state and federal laws involving drug sentencing, access to sterile syringes to reduce HIV/AIDS, access to drug treatment, prevention of overdose fatalities, and all aspects of marijuana policy. Nadelmann also plays a key role as drug policy advisor to George Soros and other prominent philanthropists as well as elected officials ranging from mayors, governors and state and federal legislators in the U.S. to presidents and cabinet ministers outside the U.S.

POSTER PRESENTATIONS**BOARD #**

<i>Amaliya, Amaliya ; Syawqie, Achmad</i>	101
Emerging Needs for Regulation of E-liquid Home Industry To Ensure Safety Among E-cigarette Users in Indonesia	
<i>Amaliya, Amaliya ; Syawqie, Achmad ; van der Velden, Ubele</i>	102
Clove Cigarette Smoking Habits and Periodontal Bone Loss In A Rural Population in Indonesia	
<i>Beacher, Felix ; Colman, Sam ; Magnani, Pierpaolo ; Kallischnigg, Gerd ; Ramazzotti, Antonio</i>	103
Intention to Use the Tobacco Heating System, Associated with Variants of a Potential Product Brochure	
<i>Beacher, Felix ; Colman, Sam ; Magnani, Pierpaolo ; Kallischnigg, Gerd ; Ramazzotti, Antonio</i>	104
Perceived Health Risk of the Tobacco Heating System and Comparators	
<i>Bebenek, Patryk</i>	105
Nicotine concentrations in the mainstream and sidestream smoke of different tobacco products, in accordance to the real smoking topography	
<i>Bebenek, Patryk</i>	106
A new way of "tobacco smoking" - the popularity of heat not burn devices in Poland	
<i>Camacho, Oscar M ; Murphy, James ; Proctor, Christopher ; Hill, Andrew</i>	107
Using a population model to assess the impact of "dual use" of e-cigarettes with conventional cigarettes	
<i>Cooney, Sarah Elizabeth; Foster, Mark; Nichol, James; Liu, Chuan; McAdam, Kevin; Murphy, James; Proctor, C.</i>	108
Characterising novel tobacco heating products – a 5-step approach to looking at aerosol formation by heating	
<i>Diamantopoulou, Eleni ; Barbouni, Anastasia ; Farsalinos, Konstantinos</i>	109
Patterns of e-cigarette use and biochemically-verified smoking status of a random sample of vapes shops customers in Greece	
<i>Donelli, Andrea; Tran, Cam Tuan; Haziza, Christelle; Ancerewicz, J.; de la Bourdonnaye, G.; Weitkunat, R.; Lüdicke, F.</i>	110
Biomarker of exposure reductions upon switching from cigarettes to a carbon heated tobacco product	
<i>Edmiston, Jeffrey; Liang, Qiwei; Liu, Jianmin; Zhao, Yuxi; Sarkar, Mohamadi</i>	111
Methodological considerations for identifying likely users of e-vapor products for ambulatory clinical studies	
<i>Farrimond, Hannah Rachel ; Abraham, Charles</i>	112
'E-cigarette friendly' stop smoking services: The opportunities and barriers to incorporating e-cigarettes into health-care systems	
<i>Fearon, Ian Michael</i>	113
Assessment of exposure to smoke toxicants in users of the gloTM tobacco heating product	
<i>Fisher, Michael; Tan-Torres, Susan; Sarkar, Mohamadi</i>	114
Health Risks Associated with the Use of Smokeless Tobacco Products	

Science posters - meet the poster presenters: Friday, 13:30 - 14:30

<i>Gentry, Sarah</i>	115
"Are electronic cigarettes an effective aid to smoking cessation or reduction among vulnerable groups? A systematic review and narrative synthesis of quantitative and qualitative evidence"	
<i>Gillman, Gene ; Tayyarah, Rana ; Morton, Michael</i>	116
CORESTA E-Vapour Sub-Group Collaborative Study Results	
<i>Greenhill, Richard ; Dawkins, Dr Lynne ; Notley, Dr Caitlin ; Finn, Dr Mark D. ; Turner, Dr John J. D.</i>	117
How and why do UK parents tolerate their adolescent children's vaping behaviours? A preliminary qualitative exploration	
<i>Greenhill, Richard ; Dawkins, Dr Lynne ; Notley, Dr Caitlin ; Finn, Dr Mark D. ; Turner, Dr John J.D.</i>	118
"Well, it's certainly nothing that's evidence-based anyway": A qualitative exploration of UK vapers' views towards the TPD	
<i>Guitton, Pierre-Marie</i>	119
CORESTA - A global scientific approach	
<i>Halliday, Jaydene; Denneval, Charline; Chappell, Colin</i>	121
Health Criteria Values and the Toxicological Implications of eLiquid Ingredients	
<i>Harang-Eltz, Marie; Scheck, Alexandre; Abulféda, Julien</i>	122
A protocol to a 6-month assessment of a new double-tank smart electronic cigarette in 100 smokers	
<i>Holliday, Richard ; Campbell, James</i>	123
Effect of nicotine on human gingival and periodontal fibroblasts and epithelial cells. A systematic review of the literature.	
<i>Holton, Samuel; Costigan, Sandra</i>	124
Case studies highlighting the importance of e-liquid flavour stewardship and risk assessment	
<i>Kimber, Catherine Franciane ; Soar, Kirstie ; Corcoran, Olivia ; Dawkins, Lynne E</i>	125
Cigalikes versus Tank Systems: Effects on Smoking Reduction, Self-Reported Satisfaction, Craving and Withdrawal Relief at the Early Stage of a Quit Attempt	
<i>Kosmider, Leon</i>	126
Exposure to heavy metals in cigarette smokers who switched to electronic cigarettes	
<i>Lalo, Helene; Soulet, Sebastien; Casile, Carine; Pairaud, Charly</i>	127
Correlation between vapers' behavior and production of degradation products (carbonyls, VOCs)	
<i>Largo, Ed; Gogova, Maria; Apkarian, Linda; Valente, John</i>	128
Cigarette Smoking Behavior Among Ever Triers of E-Cigarettes	
<i>Lipowicz, Justyna</i>	129
The influence of media on the perception of e-cigarettes industry in 2016 in Poland.	
<i>Lipowicz, Sebastian; Duda, Robert; Wolski, Tadeusz</i>	130
Optimal conditions for using e-liquid, a milestone to improve product safety	

POSTER PRESENTATIONS**BOARD #**

<i>Marczylo, Tim; Zhuikova, Elizabeth; Durrant, P.; Kovatsi, L.; Liu, Lichan; Ioannides, A.; Ioannides, C.; Goldsmith, N.; Bailey, A.</i>	131
Multi-disciplinary studies into the toxicological and neurobehavioral effects of e-cigarette use	
<i>Miller, John; Wilkinson, Walt; Wilkinson, Celeste; Sink, Kathlen; Skapars, Jim; Anderson, A.; Gardner, W.; Karles, G.</i>	132
Impact of Puffing Parameters on E-cigarette Aerosol Chemistry	
<i>Murphy, Marina</i>	133
Comparing the composition of aerosol from an e-cigarette with cigarette smoke: toxicant levels are on average 95% lower in Vype ePen emissions compared to smoke	
<i>Prieto, Luis; van der Plas, Angela Maria; Skiada, Dimitra; Benzimra, M.; Dobrynina, M.; Tudor, D.; Weitkunat, R.; Luedicke, F.</i>	134
Post-market assessment of the Tobacco Heating System 2.2 (THS) use in Japan	
<i>Proctor, Christopher</i>	135
A framework for assessing the reduced risk potential of e-cigarettes at individual and population levels	
<i>Ramstrom, Lars</i>	136
Conceivable saving of lives in the EU if there had not been a ban on snus	
<i>Roulet, Steve; Magnani, Pierpaolo; Kallischnigg, Gerd; Dugan, A.; Gage, C.; Kanitscheider, C.; Apecechea, M.; Ramazzotti, A.</i>	137
Actual use study of the candidate modified risk tobacco product (M RTP); tobacco heating system (THS)	
<i>Sarkar, Mohamadi; Liu, Jianmin; Liang, Qiwei; Gogova, Maria; Zhao, Yuxi</i>	138
Plasma Nicotine Pharmacokinetic Profiles for Various E-Vapor Products Used by Adult Smokers Under Ad-Libitum vs. Controlled Use Conditions	
<i>Soulet, Sébastien; Pairaud, Charly; Casile, Carine; Lalo, Hélène</i>	139
Characterization and influence of electronic cigarette's configuration, e-liquid's properties and users' behaviour on the quantity of vaporized e-liquid : an experimental predictive model for nicotine delivery	
<i>Syawqie, Achmad ; Winny, Yohana ; Inne, Sasmita ; Hening, Pramesti ; Kosterman, Usri ; Amaliya, Amaliya</i>	140
Risk Assessment of Electronic Cigarette Ingredients and Their Reactions to Heating	
<i>Teichert, Axel; Brossard, Patrick; Felber Medlin, Loyse; Sandalic, L.; Ancerewicz, J.; Franzon, M.; Wynne, C.; Laugesen, M.</i>	141
Evaluation of Nicotine Pharmacokinetics and Subjective Effects following Use of a Novel Nicotine Aerosol System	
<i>Trofimov, Aleksei V. ; Berdnikova, Nadezhda G. ; Menshov, Valerii A. ; Novikov, Kirill N. ; Yablonskaya, Olga I.</i>	142
Ecomonitoring the electronic nicotine delivery systems for the strategy of nicotine replacement therapy for smoking COPD patients	
<i>Wadkin, Rhys</i>	143
Comparison of Methods for Carbonyls Quantitation in Electronic Cigarette Aerosol	
<i>Ward, Emma Louise ; Notley, Caitlin ; Dawkins, Lynne ; Holland, Richard</i>	144
An ethnographic observational study of smoking cessation advice given in vape shops	
<i>Zhuikova, Elizabeth ; Bailey, Alexis ; Ioannides, Costas ; Marczylo, Tim</i>	145
Effects of nicotine and E-C cigarette fluids on cytochromes P450 in hCMEC/D3 blood-brain barrier	

Science posters - meet the poster presenters: Friday, 13:30 - 14:30

Mr Hon Lik is the Chinese pharmacist who invented the modern electronic cigarette. In 2001, while using high-dose nicotine patches to help himself stop smoking, he devised a system on a large console, using food additives as solvents. The challenge was managing to scale the mechanism down to a miniature size, suitable for a hand-held cigarette-sized device, and getting the right dose of nicotine, while also getting the right odours from additives.



In 2000, he came up with the idea of using a piezoelectric ultrasound-emitting element to vaporize a pressurized jet of liquid containing nicotine diluted in a propylene glycol solution. Hon also proposed placing the liquid in a disposable plastic cartridge, which serves as a reservoir and mouthpiece. These inventions are the basis of the present-day electronic cigarettes. In 2003, Hon filed the first patent in 2003 in China for the device and the first electronic cigarette was manufactured that year in Beijing.

We are delighted that he can join us again for the conference this year.

Conference Programme

THURSDAY, 15 JUNE

11:00 - 14:00	Registration – tea and coffee served
14:00 - 17:00 PUBLIC EVENT	<p>First International Symposium on Nicotine Technology</p> 
14:00 - 17:00	International Network of Nicotine Consumer Organisations - general meeting
17:00 - 18:15	Break
18:15 - 19:30	<p>Michael Russell Memorial Oration 2017 & Presentation of the INNCO Advocates of the Year Awards 2017</p> <p>Introduction: Professor Gerry Stimson (UK) Lecture: Dr Ethan Nadelmann (US) - Drug control and tobacco control: parallels, reform and advocacy Response: Dr Alex Wodak (Australia) INNCO Awards: Presented by Dr Ethan Nadelmann</p>
20:00 - 24:00	Conference Social Event
	GFN Social Event at Sphinx Restaurant

8:15 - 9:15	Registration
9:15 - 11:00	Official Opening & Science Plenary 1
	Opening
Welcome	Professor Dave Sweanor (<i>Canada</i>) - Chair of GFN
	New nicotine products: health and population effects
Chair	Professor Linda Bauld (<i>UK</i>)
Presenter	Dr Peter Lee (<i>UK</i>) - the health effects of snus: a review of the evidence
Presenter	Dr Lion Shahab (<i>UK</i>) - toxicant and carcinogen exposure in nicotine replacement therapy and e-cigarettes users compared with smokers and never smokers
Presenter	Dr Konstantinos Farsalinos (<i>Greece</i>) - toxicant exposure: a comparison between e-cigarettes and heat not burn technology
Presenter	Dr Moira Gilchrist (<i>Switzerland</i>) - heated tobacco technology: science, behavior and avoiding unintended consequences

11:00 - 11:30	Break
---------------	--------------

11:30 - 13:00	Science Parallel 1	Policy, Advocacy & Practice Parallel 1
	Novel methods for research into lower risk products	International policy and advocacy issues
Chair	Riccardo Polosa (<i>Italy</i>)	Charles Hamshaw-Thomas (<i>UK</i>)
Presenter	Dr Tom Kirchner (<i>US</i>) - nicotine replacement meets smoking displacement: Novel methods to understand dual-use of e-cigarettes and cigarettes	Jeannie Cameron (<i>UK</i>) - FCTC 5.3, what does it mean for you?
Presenter	Professor Kevin McGirr (<i>US</i>) - tobacco intervention for persons with serious mental illness: what works?	Judy Gibson (<i>UK</i>) - consumers and WHO COP7: challenges in establishing an international consumer organisation
Presenter	Justyna Lipowicz (<i>Poland</i>) - 'image is everything', the influence of media on the perception of the e-cigarette industry in Poland in 2016	Atakan Befrits (<i>Sweden</i>) - lost in translation: why Swedes don't like to talk about 'harm reduction'
Presenter	Amelia Howard (<i>Canada</i>) - using the tobacco industry's past to control the vaping industry's future	John Boley (<i>Australia</i>) - the lexicography of harm reduction
Presenter	Dr Thomas Mc Grath (<i>Switzerland</i>) - what is combustion?	Deborah Arnott (<i>UK</i>) - the UK: post the EU TPD and pre-Brexit
Presenter		Professor Gerry Stimson (<i>UK</i>) - challenging a bad law: the EU ban on the sale of snus

13:00 - 14:30	Lunch Break
13:30 - 14:30	Science posters - meet the poster presenters

14:00 - 15:30		Science Parallel 2	Policy, Advocacy & Practice Parallel 1
		Lower risk products in practice	Addressing problems and finding creative responses
Chair		Joe Gitchell (<i>US</i>)	Jessica Harding (<i>UK</i>)
Presenter		Dr Richard Holliday (<i>UK</i>) - dental professionals' opinions towards smoking cessation and e-cigarettes: a UK survey	Dr Marina Foltea (<i>Switzerland</i>) - banning e-vapour products: implications under international trade rules
Presenter		Catherine Kimber (<i>UK</i>) - cigalikes vs tank systems: effects on smoking reduction, self-reported satisfaction, cravings and withdrawal relief	Professor Rajesh N. Sharan (<i>India</i>) - tobacco and the prospects for harm reduction in India
Presenter		Dr Joanna Miler (<i>UK</i>) - vapers helping smokers: cascading the benefits of e-cigarettes	Gillian Golden (<i>Ireland</i>) - a snapshot of tobacco harm reduction in Ireland
Presenter		Dr Caitlin Notley (<i>UK</i>) - the unique contribution of e-cigarettes for avoiding relapse to smoking – consumer experiences of quitting, switching, dual using, and 'permissive lapse' on the path to maintaining abstinence	Professor Solomon Rataemane (<i>South Africa</i>) - developing tobacco harm reduction in South Africa
Presenter		Louise Ross (<i>UK</i>) - the first ecig-friendly stop smoking service: what we achieved in 3 years	Nancy Sutthoff (<i>New Zealand</i>) - how New Zealand shifted its policy on nicotine products
Presenter			Associate Professor Colin Mendelsohn (<i>Australia</i>) - nicotine, the TGA and a missed opportunity in Australia

15:30 - 16:00

Break

16:00 - 17:30

Panel Discussion

16:00 - 17:30		Panel Discussion
		Nicotine futures - the tobacco industry and public health
Moderator		Martin Cawley (<i>UK</i>)
Presenter		Professor Dave Swenor (<i>Canada</i>) - the tobacco industry and public health: engagement or opposition?
Responder		Cynthia Cabrera (<i>US</i>)
Responder		Dr David O'Reilly (<i>UK</i>)
Responder		Dr Alex Wodak (<i>Australia</i>)
Responder		Julie Woessner (<i>US</i>)

17:30 - 19:00

Networking Reception

Drinks and canapes

9:30 - 11:00		Policy Plenary 1
	Difference and diversity: tobacco harm reduction in different contexts	
Chair	Martin Dockrell (UK)	
Presenter	Helen Redmond (UK) - mental health, nicotine use and e-cigarettes	
Presenter	Professor Ron Borland (Australia) - trying to understand the rapidly emerging vaping culture: findings from the ITC project.	
Presenter	Dr Lars Ramstrom (Sweden) - 50 years of increasing snus use in Swedish men – impact on smoking and public health	
Presenter	Professor Linda Bauld (UK) - e-cigarette use during pregnancy	
11:00 - 11:30		Break

11:30 - 13:00		Science Plenary 2
	Nicotine - past, present and future	
Chair	Sarah Jakes (UK)	
Presenter	Professor Neal Benowitz (US) - harms and risks of nicotine? Implications for tobacco harm reduction	
Presenter	Professor Eric Donny (US) - reducing nicotine in cigarettes to enable positive behaviour change	
Presenter	Dr Michael Hufford (US) - can you believe that they used to smoke it? The future of recreational and therapeutic nicotine consumption.	
Responder	Dr Sharon Cox (UK)	

13:00 - 14:00		Lunch Break
---------------	--	-------------

14:00 - 15:30		Policy Plenary 2
	Regulatory models and hurdles: navigating the regulatory maze	
Chair	Dr Attila Danko (Australia)	
Presenter	Peter Beckett (UK) - why regulate?	
Presenter	Patricia Kovacevic (US) - legal remedies in the United States – challenging the FDA	
Presenter	Cecilia Kindstrand-Isaksson (Sweden) - are regulations fit for purpose? Borderline and novel products, markets and consumers	
Presenter	Clive Bates (UK) - what would good regulation look like?	
15:30 - 15:45		Break

15:45 - 16:30		Closing Session
Chair	Professor Dave Swenor (Canada) - Chair of GFN	
Presenter	Harry Shapiro (UK) - Conference Rapporteur	
Presenter	Joe Gitchell (US), Olivier Théraulaz (Switzerland), Louise Ross (UK)	

DEBORAH ARNOTT, ACTION ON SMOKING AND HEALTH (ASH), UK

Deborah Arnett is Chief Executive of Action on Smoking and Health (UK), honorary associate professor in the Division of Epidemiology and Public Health at the University of Nottingham, honorary fellow of the Royal College of Physicians and member of the RCP's Tobacco Advisory Group. A recognised international expert on tobacco control and the WHO FCTC, she has a particular interest in nicotine regulation and harm reduction. She was a member of the NICE committee which developed the guidance on Tobacco Harm Reduction and of the Commission on Human Medicines expert advisory group to the MHRA on nicotine containing products.



CLIVE BATES, COUNTERFACTUAL CONSULTING, UK

Clive Bates has had varied career having worked in the private sector for IBM, in the UK government in Tony Blair's Strategy Unit, the United Nations in Sudan, for Greenpeace and for Action on Smoking and Health in the UK, which is why he is interested in smoke free alternatives to tobacco. Since early 2013 he has his own public interest consultancy and advocacy organisation, including the Counterfactual blog. He is interested in the enormous public health potential of tobacco harm reduction and is not engaged by pharmaceutical, e-cigarette or tobacco interests.



PROFESSOR LINDA BAULD, UNIVERSITY OF STIRLING & UK CENTRE FOR TOBACCO AND ALCOHOL STUDIES, UK

Linda Bauld is Professor of Health Policy, Director of the Institute for Social Marketing and Dean of Research (Impact) at the University of Stirling in Scotland. She is also Deputy Director of the UK Centre for Tobacco and Alcohol Studies and holds the CRUK/BUPA Chair in Behavioural Research for Cancer Prevention at Cancer Research UK. She has conducted research on smoking cessation and tobacco control for 20 years, is a former UK government scientific advisor on tobacco control and chaired the NICE guidance group on tobacco harm reduction. She is Deputy Editor of the journal Nicotine and Tobacco Research and President-Elect of the Society for Research on Nicotine and Tobacco Europe.



PETER BECKETT, POLICYMATTERS, UK

Peter Beckett is a consultant who specialises in the identification, analysis and management of political risk. He spent nearly three years as Head of Public Policy for ECITA, where he was responsible for industry-level political advocacy during the procedure that led to the passage of the Tobacco Products Directive. He has also been instrumental in its implementation, is an expert in compliance with its requirements and was at the centre of negotiations that led to the formation of CEN TC 437 on electronic cigarettes and e-liquids. He also works with the US Vapor Technology Association, and consults for leading nicotine delivery companies around the world.



ATAKAN BEFRITS, SWEDEN

Atakan Erik Befrits is a Turkish/Swedish tobacco harm reduction advocate, policy researcher and harm reduction entrepreneur. Mr Befrits works for the global recognition and adoption of tobacco harm reduction as a vital and crucial tool for better public health and argues that tobacco harm reduction is clearly stipulated as mandatory in the Framework Convention on Tobacco Control. His primary area of advocacy is to internationally provide information on food grade smokeless tobacco (aka snus or snus-analog products) being viable, affordable and 98% harm reduced alternatives to smoking.



PROFESSOR NEAL BENOWITZ, UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, US

Neal L. Benowitz, MD, is Professor of Medicine and Bioengineering & Therapeutic Sciences, and Chief of the Division of Clinical Pharmacology and Experimental Therapeutics, University of California, San Francisco (UCSF). He received his medical degree from the University of Rochester School of Medicine in 1969. He completed a postdoctoral fellowship in clinical pharmacology at UCSF and joined the faculty in 1974. His research interests have focused primarily on the human pharmacology and toxicology of nicotine. He has published more than 600 research papers. Dr Benowitz also maintains an active clinical practice in cardiovascular medicine and medical toxicology.




JOHN BOLEY, FACTASIA, HONG KONG

John Boley has a background in journalism. An experienced TV/video presenter, producer and writer, he has worked on a wide range of contentious issues, including vehicle emissions and sustainability in Asia's tourism industry. Based in Asia for 20 years, he co-founded FactAsia with Heneage Mitchell in 2012 as both saw issues increasingly misrepresented and consumer rights trampled on.



PROFESSOR RON BORLAND, THE CANCER COUNCIL VICTORIA, AUSTRALIA

Ron Borland PhD is the Nigel Gray Distinguished Fellow in Cancer Prevention, at The Cancer Council Victoria, Australia where he has worked for 30 years. He is listed in the Thomson-Reuters List of the World's most influential scientists. He is one of the Principal Investigators of the International Tobacco Control Policy Evaluation Project: an international collaboration that is analysing the impact of policies on smoking. His has a special interest in harm minimisation strategies and strategies to assist highly disadvantaged, high smoking prevalence groups. He is the developer of CEOS theory: a comprehensive theory of Hard to Maintain Behaviour Change.



CYNTHIA CABRERA, THE CATING GROUP, US

Cynthia Cabrera is a seasoned expert in the vapor space, involved in the vapor industry since 2011. As Founder and president of The Cating Group, Cynthia and her team provide business-consulting services including compliance, manufacturing operations, restructuring, government affairs, and business development including new product rollout and strategic partnerships. She is a frequent speaker on trends, product evolution, distribution channels, and regulatory and legislative issues. Cynthia has presented for TMA, GTNF, GFN, FDLI, RRF, ECIG USA, the Morven Dialogues and a wide variety of vapor shows and exhibits.



JEANNIE CAMERON, JCIC INTERNATIONAL, UK

Jeannie Cameron is founder and managing director of JCIC International Ltd; a UK based strategic advocacy consultancy specializing in tobacco harm reduction, anti-illicit trade and supply-chain security. For 10 years until 2011 Jeannie was responsible for worldwide advice on all aspects of the FCTC treaty and Protocol including leading delegations to Geneva negotiations and is a known FCTC expert. In 2007 Jeannie received a distinction for her Masters in Law (LLM) dissertation on Human Rights, Harm Reduction and FCTC, and continues to advocate about the legal basis on which the FCTC requires Parties to implement harm reduction strategies as part of national tobacco control policies.



MARTIN CAWLEY, BIG LOTTERY FUND, UK

Martin Cawley joined the Big Lottery Fund in September as Director for Scotland following a successful period as chief executive of Turning Point Scotland. Martin has worked in practitioner, management and leadership positions in both the statutory and voluntary sectors for over 34 years. Martin has extensive experience of developing and managing person centered services designed to support people achieve full and active citizenship. Over the years he has also been a board member of a number of smaller organisations including national umbrella agencies and social enterprises aimed at improving practice and approach and influencing social policy.



SPEAKERS & CHAIRS



DR SHARON COX, CENTRE FOR ADDICTIVE BEHAVIOUR RESEARCH, LONDON SOUTH BANK UNIVERSITY, UK

Dr Sharon Cox has over ten years' experience working in the drug and alcohol field, including working at front-line services with some of the UK's most deprived communities. She has a special interest in harm-reduction and advocates for improving lives through transparency and opportunity. She currently works as a Cancer Research UK Funded Research Fellow at London South Bank University's Centre for Addictive Behaviour Research. Her current research is focused on e-cigarette puffing patterns associated with high and low nicotine e-liquid strength, effects on toxicant and carcinogen exposure.



DR ATTILA DANKO, NEW NICOTINE ALLIANCE, AUSTRALIA

Dr Attila Danko is an experienced, busy General Practitioner in Ballarat, a regional city in Australia. Over the last few years, several of his patients have surprised him by being able to give up smoking using electronic cigarettes when all other methods had failed. Inspired by the potential revolution in smoking cessation this represents, and appalled by the prohibitionist policies of his country, he began to advocate for the liberalisation of laws in Australia that effectively ban nicotine containing electronic cigarettes. He receives no payment or any inducement whatsoever from any Pharmaceutical, Tobacco or Electronic cigarette company.



MARTIN DOCKRELL, PUBLIC HEALTH ENGLAND, UK

Martin Dockrell has been involved in public health since the mid 1980's. He started in community based responses to HIV/AIDS and moved through respiratory health and patient advocacy to tobacco control. He is former Director of Policy & Research at Action on Smoking and Health.



PROFESSOR ERIC C. DONNY, DEPARTMENT OF PSYCHOLOGY, UNIVERSITY OF PITTSBURGH, USA

Dr. Eric C. Donny is a Professor of Psychology, Psychiatry and Behavioral & Community Health Sciences at the University of Pittsburgh. His expertise includes behavioral pharmacology, biological and health psychology, addiction, and regulatory science. His current interests focus on regulatory approaches to reducing the health burden of tobacco. He co-directs the Center for the Evaluation of Nicotine in Cigarettes (CENIC), an NIDA/FDA-funded cooperative agreement that aims to increase understanding of how behavior and health might be affected if the nicotine content of combustible tobacco products is reduced.



DR KONSTANTINOS FARSALINOS, ONASSIS CARDIAC SURGERY CENTER, ATHENS, GREECE

Dr Konstantinos Farsalinos is a cardiologist, working as researcher at Onassis Cardiac Surgery Center in Athens-Greece and at Medical Imaging Research Center, University Hospital Gathuisberg in Leuven-Belgium. His main research interests are new modalities in cardiovascular imaging and he has received a scholarship from the Greek Society of Cardiology for research and education in this field. He has studied the effects of smoking on subclinical cardiac dysfunction using new imaging techniques since 2010.



DR MARINA FOLTEA, TRADE PACTS, SWITZERLAND

Dr. Marina Foltea is founder and Managing Director at Trade Pacts, a trade and investment consultancy based in Geneva, Switzerland and a researcher with R-Street Institute, Washington. Marina obtained her Ph.D. in International Economic Law from the University of Bern, Switzerland. Marina takes continuous keen interest on how international trade law interfaces with other fields of law and policy, in particular health and environment. She is frequent speaker in both academic and business related events. Since 09/2016 she is on the Indicative List of WTO Panels, which makes her eligible to solve disputes between Member States at the World Trade Organisation in Geneva.



JUDY E. GIBSON, INTERNATIONAL NETWORK OF NICOTINE CONSUMER ORGANISATIONS (INNCO), UK

Since gaining her Brownie Wings in the 60's, Judy Gibson has had an eclectic career including: WRAF Aircraft mechanic, drill instructor, restaurant manager, detective sergeant, MOD/M15 gopher, Computer Consultant, twenty years in artiste management, theatre marketing/film programming and finally a Community Flood Consultant before reaching the zenith that is INNCO. A Jill of all trades and occasional mistress seems to cover it. A smoker since the invention of bike-sheds, Judy tried vaping about six years ago, reducing smoking but struggling with e-cigarette incarnations until, in 2015, technological improvements tipped the scales.



MOIRA GILCHRIST, PMI, SWITZERLAND

Dr. Moira Gilchrist was appointed Vice President Reduced Risk Products Corporate Affairs in January 2017. Prior to this she was based in R&D where she was Director of Scientific Engagement from 2014 to 2016. Since joining PMI in 2006, Dr. Gilchrist has worked exclusively on our Reduced-Risk Product program in roles related to Research and Development as well as Commercialization. Prior to joining PMI, Dr. Gilchrist worked in the pharmaceutical sector for more than 10 years. She was a Principal Consultant in PwC and IBM's pharmaceutical industry consulting groups and prior to that held positions in both industry and charity sectors developing new drug formulations.



JOE GITCHELL, PINNEY ASSOCIATES, US

Joe Gitchell provides strategic counsel to clients across a wide range of health policy, regulatory, and marketing and communications challenges. With a focus on client service, Joe leads efforts supporting regulatory approvals, conducting public policy analysis, developing communications approaches, devising, refining and defending claims, and providing input on strategic market opportunities and directions. He has counseled clients navigating health policy and communications challenges in the US, Europe, Latin America, Asia and the Middle East.



GILLIAN GOLDEN, IRISH VAPE VENDORS ASSOCIATION, IRELAND

Gillian Eva Golden comes from a background in the creative, customer service, and retail sectors. A former smoker thanks to discovering vaping in 2012, she now works as administrator for the Irish Vape Vendors Association, Ireland's only trade association for independently owned, specialised retailers of vaping products. She not only advocates for vaping as a means of tobacco harm reduction, but also for industry stewardship, and sits on the Technical Committee of CEN TC 437 for electronic cigarettes and e-liquids.



CHARLES HAMSHAW-THOMAS, NICOPURE LABS, UK

Charles Hamshaw-Thomas is the Head of Corporate and Legal Affairs for Europe at Nicopure Labs. Charlie was previously Corporate Affairs, Business Development and Legal Director for E-Lites, the brand at the forefront of the UK vaping industry's explosive early growth beginning in 2012. Prior to that, he was Principal of CSR Solutions, a corporate social responsibility consultancy business. Having qualified as a lawyer in London with Slaughter and May, Charlie subsequently held senior management positions with some of the UK's largest public companies. Charlie is currently also Acting Secretary General for UKVIA (the UK Vaping Industry Association).

JESSICA HARDING , NEW NICOTINE ALLIANCE, UK

Jessica Harding became NNA's first administrator in December 2016. She is passionate about the potential for tobacco harm reduction products to improve lives and has devoted much her time and energy to vaping consumer activism. She helped establish Vapers in Power, and helped to get VIP registered as a political party. Her primary role in NNA is fundraising, external communications, helping NNA campaigns, and supporting the work and development of NNA. Before having children she worked as an English teacher, in the UK and abroad.



DR RICHARD HOLLIDAY, NEWCASTLE UNIVERSITY, UK

Richard Holliday is a Speciality Registrar (StR) in Restorative Dentistry and NIHR Doctoral Research Fellow at Newcastle University. Richard's research interests are focused on periodontal diseases, particularly risk factors, and he is currently completing his PhD on 'e-cigarettes as a smoking cessation or harm reduction tool for patients with periodontitis'. The main body of this work is a feasibility randomised controlled trial of 80 smokers with periodontitis. Additional projects include surveys of tobacco education in UK dental schools, surveys of practitioner opinions and in vitro analysis.



AMELIA HOWARD, UNIVERSITY OF WATERLOO, CANADA

Amelia Howard is a PhD candidate in Sociology at the University of Waterloo (Ontario, Canada). Her dissertation explores the social history of vapor technologies. Specifically, she is interested in the role played by "lead-users" in product innovation and in shaping the consumer market, the political and cultural dynamics of controversies surrounding the regulation of e-cigarettes, and the implications of various regulatory regimes for innovation and knowledge making practices in the vaping space. Amelia advocates for harm reduction policies that, in addition to making products available to consumers, recognize and protect users' ability to innovate in the market.



DR MICHAEL HUFFORD, PINNEY ASSOCIATES, US

Michael Hufford has more than 20 years of experience in clinical research, drug and medical device development, and behavioral science across a wide range of therapeutic areas. He is currently Vice President of Regulatory Affairs, Behavioral Science and Innovation at Pinney Associates, and also an Entrepreneur in Residence at the University of Pittsburgh. Michael has co-founded multiple pharmaceutical, medical device, and mobile health companies, including of e-Nicotine Technology. Michael earned his undergraduate degree from Purdue University, and his master's and doctoral degrees in clinical psychology from the University of Pittsburgh.



SARAH JAKES, UK

Since leaving school 'a very long time ago' Sarah Jakes has worked in the shipping industry, the foreign exchange market and now runs her own business in property management. A smoker of some 35 years Sarah switched to vaping in 2013, only to find that the choice of this safer alternative for smokers was under threat from excessive and ill founded regulation. Having joined forces with other consumers in the battle against over regulation in the EU parliament, she is convinced that a better understanding of e-cigarettes and other harm reduced products among key influencers & decision makers is required if these products are ever to reach their full potential for public health gains.



CATHERINE KIMBER, UNIVERSITY OF EAST LONDON, UK

Catherine Kimber is a Doctoral candidate at the School of Psychology at the University of East London. Her research is concerned with nicotine and smoking addiction with a focus on e-cigarette use. Earlier work looked at the relationship between e-cigarette types and their appeal to smokers. She has also been involved in other work which includes the effects of nicotine on smokers' cognitive functioning. Her PhD is looking at compensatory behaviours in e-cigarette use, nicotine delivery and e-cigarettes' efficacy as smoking cessation aids.



CECILIA KINDSTRAND-ISAKSSON, SWEDISH MATCH, SWEDEN

Cecilia Kindstrand is Director of Public Affairs for Swedish Match, a tobacco company with tobacco harm reduction at the core of its business. She is based in Brussels and has worked extensively with the revision of the EU's Tobacco Products Directive, a legislation banning the 'proof of concept' of tobacco harm reduction in 27 of the 28 Member States. The vision of Swedish Match is A World Without Cigarettes.



DR THOMAS KIRCHNER, NEW YORK UNIVERSITY, US

Thomas R. Kirchner, PhD, is Clinical Associate Professor of Public Health, Medicine, and Urban Science at NYU, and founding director of NYU mobile health (mHealth). Dr. Kirchner is a clinical-health psychologist and methodologist interested in the analysis and graphical representation of "intensive" longitudinal and geographic data, including novel methodologies that link individual behavior to the real-time context in which it occurs. Dr. Kirchner's approach targets momentary influences on the maintenance of addictive and health-related behavior utilizing both field-based (ecological momentary assessment) and laboratory-based paradigms.



PATRICIA I. KOVACEVIC, NICOPURE LABS LLC, US

Patricia I. Kovacevic, Esq. is the General Counsel and Chief Compliance Officer of Nicopure Labs LLC. With extensive U.S. and international industry experience, she held senior legal and compliance positions at, among other, Philip Morris International and Lorillard. Her expertise includes global e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy, product development and launch. Ms. Kovacevic serves on the advisory board of the Global Tobacco and Nicotine Forum and on the board of the Vapor Technology Association.



DR PETER N LEE, P.N.LEE STATISTICS AND COMPUTING, UK

Peter Lee is an epidemiologist/medical statistician who has published widely, principally on tobacco. He went to Oxford, and after working for the Tobacco Research Council, formed his independent consultancy company P.N.Lee Statistics and Computing in 1982. He edited reference books on international smoking prevalence. He has published numerous meta-analyses on health effects, not only of smoking and quitting, but also of passive smoking and smokeless tobacco. Accuracy of diagnosis and self-reported smoking habits is a major interest. He has won national titles at both chess and bridge. He is married with one daughter and two grandchildren.



JUSTYNA LIPOWICZ, LIPRO E-LIQUID PRODUCTION, POLAND

Involved in e-cigarette industry since 2012. Justyna Lipowicz is co-founder of the first Polish e-liquid on the Polish market in serial production. Using more than 30 years of production experience, she manages a manufacturing enterprise which is one of the leading producers of liquids for electronic cigarettes on the Polish market. Justyna has been a speaker at trade events, among others, the Vape Expo Poland conference. She is also an active participant of the Global Forum on Nicotine and a member of the International Technical Committee CEN/TC 437, which is responsible for developing the European quality standard for "Electronic cigarettes and e-liquids".



SPEAKERS & CHAIRS



DR THOMAS MC GRATH, PHILIP MORRIS INTERNATIONAL, SWITZERLAND

Dr Thomas Mc Grath is Manager Reduced Risk Products (RRPs) at Philip Morris International (PMI). He joined PMI in 2005 and has worked in a variety of roles focused on the development, assessment and, most recently, commercialization of PMI's RRP's. He has more than 10 years of experience working on research related to heating tobacco without combustion and has published a number of research articles on the formation of Polycyclic Aromatic Hydrocarbons (PAHs) and phenolic compounds. Dr. Mc Grath graduated from the University of Ulster, Northern Ireland, and obtained his PhD in Chemistry from Brown University, Rhode Island, USA.



PROFESSOR KEVIN MCGIRR, UNIVERSITY OF CALIFORNIA, US

Kevin McGirr is Clinical Professor in the School of Nursing; has taught in schools of medicine, social work and public health and was a Fulbright Scholar in Pondicherry India, 2013-2014. He has over forty years experience in providing and managing behavioral health services; holds master's degrees in public health, psychiatric nursing and ABD in public health. He has been involved in the training and development of harm reduction services and in particular utilizing Harm Reduction Tobacco interventions for persons with serious mental illness.



ASSOCIATE PROFESSOR COLIN MENDELSON, UNIVERSITY OF NEW SOUTH WALES, AUSTRALIA

Colin Mendelsohn is an Associate Professor in the School of Public Health and Community Medicine at the University of New South Wales, Sydney, Australia. He is a medical practitioner and tobacco treatment specialist working in private practice. He is actively involved in raising awareness of the public health benefits of nicotine-containing e-cigarettes and advocating for their legalisation in Australia. Colin is a member of the committee that develops the Australian national smoking cessation guidelines and is past Vice President of the Australian Association of Smoking Cessation Professionals. Colin is on the steering committee of the QUIT4October stop smoking campaign.



DR JOANNA MILER, CENTRE FOR SUBSTANCE USE RESEARCH, UK

Dr Joanna Astrid Miler is a Psychologist, with research interests in addiction, harm reduction and smoking cessation. Miler holds MA and MRes degrees from the University of St Andrews and a PhD from the University of Southampton. Prior to joining the Centre for Substance Use Research she worked as an Analyst at RAND Europe, and later, as a Research Health Psychologist in the Health and Lifestyle Research Unit of Queen Mary University of London. Alongside conducting scientific research, she is also a trained specialist stop smoking advisor and worked in that capacity for the City of London Stop Smoking Service.



DR CAITLIN NOTLEY, UK SOCIETY FOR THE STUDY OF ADDICTION, UK

Dr Caitlin Notley is a Senior Lecturer in Mental Health, and a Research Fellow of the UK Society for the Study of Addiction. She has more than ten years experience in Addiction research. Her current research focus is on tobacco smoking relapse prevention, and will develop an intervention to support women to stay abstinent from smoking postpartum. Dr Notley's research interest in alternative nicotine delivery devices primarily explores social and culturally pertinent aspects of vaping, with a particular focus on the public health potential of vaping for smoking relapse prevention.



DR DAVID O'REILLY, BRITISH AMERICAN TOBACCO, UK

Dr David O'Reilly was appointed to the Management Board of British American Tobacco as Group Scientific and R&D Director, in January 2012. He graduated from Imperial College, London in 1991 with a Ph.D. in molecular virology. In recent years at BAT, O'Reilly has been a driving force behind the creation and growth of BAT's multidisciplinary global R&D effort in consumer-led, science-based innovation in next-generation tobacco and nicotine products. He has also led the company's programs in CSR, tobacco harm reduction and scientific and public health policy and engagement. He is co-founder of the Global Tobacco and Nicotine Forum and Chairman emeritus of the GTNF Advisory Board.



PROFESSOR RICCARDO POLOSA, UNIVERSITY OF CATANIA, ITALY

Prof Riccardo Polosa is a director of the Institute for Internal and Emergency Medicine of the University of Catania in Italy. He is also in charge of the University's Centre for Tobacco Research (CPCT), and Honorary Professor of Medicine at Southampton University (UK). He is author of more than 250 peer reviewed articles and books. On top of his academic work, he serves also as chief scientific advisor for Lega Italiana Anti Fumo (LIAF), the Italian Anti-Smoking League. He has been recently elected Convenor for the European Working Group on Requirements and test methods for emissions of electronic cigarettes, within the European Committee for Standardization (CEN/TC 437).



DR LARS RAMSTROM, INSTITUTE FOR TOBACCO STUDIES, SWEDEN

Lars Ramstrom is, since 1990, director of the Institute for Tobacco Studies, Stockholm, Sweden. From 1967 to 1989 Director of the National Smoking and Health Association, a governmentally supported NGO dealing with tobacco control matters. International engagements with various organizations, including WHO, participant in WHO Expert Committees, member of the WHO Expert Advisory Panel on Smoking and Health, Honorary Vice President of ICAA and chair of the ICAA Section on nicotine. Recipient of the 1988 WHO Award Medal for Achievements in Tobacco Control. Author of scientific articles and reviewer for a number of medical science journals.



PROF. SOLOMON RATAEMANE, AFRICAN PSYCHIATRIC ASSOCIATION & ALLIED PROFESSIONS, SOUTH AFRICA

Prof. Solomon Tshimong Rataemane: (President: African Psychiatric Association and Allied Professions 2014 – 2017). He is head of Department of Psychiatry, Sefako Makgatho Health Sciences University in South Africa; World Psychiatric Association (WPA) Board member and WPA Representative Zone 14 (2008 – 2014); and Chair of the WPA Section on Conflict Management and Conflict Resolution (2011 – 2018). He has special interest in addiction medicine and has served as deputy chairperson and chairperson of the Central Drug Authority of South Africa from 1995 to 2005. He is chairperson of the Ministerial Advisory Committee on Mental Health in South Africa.



HELEN REDMOND, SILVER SCHOOL OF SOCIAL WORK, NEW YORK UNIVERSITY, US

Helen Redmond is a Licensed Clinical Social Worker. She is an expert in addiction and works with drug users and people with a psychiatric diagnosis. Helen provides consultation and training in tobacco harm reduction. Her goal is to help the most marginalized smokers transition to e-cigarettes. She has written about drug policy, drug treatment and the American criminal justice system for Al Jazeera, Alternet, Harpers and The Influence. Helen is a filmmaker and she made a short documentary about people with serious mental health problems and smoking. Her documentary, Ezra Dowery: Life on Broadway, was an official selection of the NYC Mental Health Film Festival, 2016.



LOUISE ROSS, STOP SMOKING SERVICE, UK

Louise Ross is the leader of the Leicester City Stop Smoking Service. Louise finished a very happy and long working life in learning disabilities to work in tobacco control and smoking cessation, and has been delighted to discover a second career that has been even more satisfying than the first. Initially sceptical about ecigs, she has become a vocal advocate for their use as a harm reduction method, principally because she has listened to people who have used them to stop smoking, and has been utterly convinced by their sincerity. Louise is an associate of NNA UK, a charity committed to improving public health through a greater understanding of risk-reduced nicotine products.

DR LION SHAHAB, UNIVERSITY COLLEGE LONDON, UK

Dr Lion Shahab is a senior lecturer in health psychology at University College London and trained in psychology, epidemiology and neuroscience. He has more than 10 years' experience in tobacco control with a particular interest in novel behavioural and pharmacological smoking cessation interventions, biomarkers, tobacco product regulation and policy and tobacco use epidemiology. Dr Shahab's research spans a variety of techniques and methods, involving both human (randomised controlled trials, survey analysis, laboratory and experimental work) and animal studies (electrophysiology). He has authored over 70 scientific papers and reviews.



HARRY SHAPIRO, DRUGWISE, UK

Harry Shapiro is Director of DrugWise an online drug information service and managing editor of D5 Daily - an online news service on drugs, alcohol and tobacco. He is an author, journalist and lecturer who has written widely on the subject of drugs. He is the author of several books relating to drugs and popular music including Waiting for the Man: the story of drugs and popular music; Shooting Stars: drugs, Hollywood and the movies; Jimi Hendrix, Electric Gypsy; Eric Clapton: Lost in the Blues and Jack Bruce: Composing Himself : the Authorised Biography.



PROFESSOR RAJESH SHARAN, NORTH-EASTERN HILL UNIVERSITY, SHILLONG, INDIA

Rajesh N. Sharan, Ph. D., is a Professor at Department of Biochemistry and Director of Design Innovation Center at North-Eastern Hill University, Shillong (India). Rajesh is a Molecular Biologist and Biochemist by training with over 3 decades of research experience in the field of betel (Areca) nut & chemical induced carcinogenesis, and molecular mechanisms of radiation induced damage to DNA & its repair with expertise in biomarker discovery for cancer and radiation damage assessment. Rajesh is a former President of Indian Society for Radiation Biology and currently a member of CRP of IAEA (Vienna). He has over 105 research publications & books, and few patents to his credit.



PROFESSOR GERRY STIMSON, NEW NICOTINE ALLIANCE, UK

Professor Gerry Stimson is a public health social scientist, with over 40 years' experience of research and advocacy. He was one of the founders of drugs harm reduction in the 1980s and helped develop and evaluate harm reduction in the UK as a response to HIV/AIDS. He has advised the UK Government, WHO, UNAIDS, UNODC, World Bank and numerous governments on issues relating to drugs, HIV infection and AIDS, and alcohol. He is an advocate for tobacco harm reduction as a key public health strategy for reducing smoking related harms. He is a member of the British Standards Institute working group on e-cigarette standards. Prof. Stimson has published over 220 scientific publications and several books.



NANCY SUTTHOFF, AOTEAROA VAPERS COMMUNITY ADVOCACY, NEW ZEALAND

Nancy Sutthoff is the Co-founder and Co-Director of Aotearoa Vapers Community Advocacy (AVCA) in New Zealand. Nancy has a diverse background with degrees in Police Sciences (A.A.S) and Sociology (B.A) she has always, in one way or another, been involved in investigative and advocacy roles, from business analysis of corporate IT systems to research administration at SUNY Stony Brook (New York, USA) to local government relations for the West Boca Community Council (Florida, USA) to youth health and education advocacy (New Zealand). Nancy's motivation has been, and always will be, to educate people on their options & to support them in their choices.



PROFESSOR DAVID SWEANOR, UNIVERSITY OF OTTAWA, CANADA

David Sweanor is an adjunct professor, Faculty of Law, University of Ottawa, Centre for Health Law, Policy & Ethics, University of Ottawa and a honorary (consultant) assistant professor, University of Nottingham. He has been actively involved in tobacco and health policy issues since the beginning of the 1980s. He has worked with numerous organisations, including the International Union Against Cancer, World Health Organization, World Bank and the Pan American Health Organization, and currently focuses much of his efforts on risk reduction strategies. He has received both international recognition and prestigious prizes for his work.



OLIVIER THERAULAZ, HELVETIC VAPE, SWITZERLAND

Olivier Théraulaz is the chairman of Helvetic Vape, the Swiss association of vapers. Long-time smoker, he learned by chance in 2013 that the Swiss prohibition on vaping products containing nicotine concerned only sales and that importations for personal use was allowed. He immediately switched to vaping and stopped smoking in less than one week without giving up his pleasure. Convinced of the potential of vaping for public health, he started to advocate for the modification of the absurd administrative Swiss rules about vaping and the dissemination of clear and objective information about risk and harm reduction.



DR ALEX WODAK, AUSTRALIAN DRUG LAW REFORM FOUNDATION, AUSTRALIA

Dr Alex Wodak AM is a retired physician who is now President of the Australian Drug Law Reform Foundation. he works full time on drug law reform as a volunteer. Together with colleagues, he started the first needle syringe programme (1986) and the first medically supervised injecting centre (1999) in Australia when both were pre-legal. Dr Wodak was President of the International Harm Reduction Association (1996-2004). He has been interested in tobacco harm reduction since 1992 but only active in THR in recent years. Dr Wodak helped to start the National Drug and Alcohol Research Centre (1987).



JULIE WOESSNER, THE CONSUMER ADVOCATES FOR SMOKE-FREE ALTERNATIVES ASSOCIATION, US

Julie Woessner is the National Policy Director and President of the Board of CASAA (The Consumer Advocates for Smoke-free Alternatives Association): a nonprofit U.S.-based public health and education NGO, which advocates for people who consume, or might in the future consume, low-risk alternatives to cigarettes. CASAA engages in policy advocacy in the U.S. involving legislative and regulatory matters to protect access to low-risk products and mobilizes its 200,000+ members to do the same. Internationally, CASAA provides education about tobacco harm reduction and advocacy. Woessner holds a JD from Duke School of Law and was previously a practicing attorney.



CONFERENCE TEAM

Gerry Stimson
Programme Director



Bisola Obileye
Finance Director



Paddy Costall
Conference Director



Joanna Junak
Conference Manager



Grzegorz Król
Technical Director



Katarzyna Kowalczyk
Media Relations Assistant



Filip Woźniak
Technical Assistant



Priya Lakhani-Quiling
Media Relations Manager



Łukasz Bieniecki
Photographer



Jon Derricott
Videographer



PROGRAMME COMMITTEES

Chair: **Gerry Stimson**, UK

Science

Linda Bauld, Scotland - Chair
Ann McNeill, UK
Konstantinos Farsalinos, Greece
Chris Bullen, New Zealand
Ryan Kennedy, US
Jacques Le Houezec, France
Lynne Dawkins, England

Policy & Advocacy

Gerry Stimson, UK - Chair
Mirek Dworniczak, Poland
Colin Mendelsohn, Australia
Joe Gitchell, US
Julie Woessner, US

Polish Host Committee

Andrzej Sobczak, Poland
Mirek Dworniczak, Poland

Consumer Engagement

Judy Gibson, UK

INNCO

Advocates of the Year Awards 2017

International Network of Nicotine Consumer Organisations

Responsibility for overseeing the fifth GFN advocacy awards has been passed to the International Network of Nicotine Consumer Organisation (INNCO). We were honoured to accept the task, and see it as an endorsement of INNCO - a global umbrella, now representing twenty seven national organisations across five continents.

Conceived at GFN16, INNCO was launched last September to coincide with the WHO FCTC COP7 in Delhi. It now seems a very long time ago, although memories of the 'impenetrable smog' are likely to linger...

Advocating for nicotine harm reduction can often seem a thankless task. In fact, let's be honest, it is a thankless task! Despite being remorselessly denounced as shills for 'something', none of us does it for the money! Some work quietly in the background, others rage lyrically on social media and some excel in delivering blindingly brilliant written arguments, but all are driven by a shared passion. They believe that tobacco harm reduction can be advanced by switching to safer nicotine products, smokers have a right to access them, consumers have a right to continue using them and everyone deserves the right to truthful, unbiased, verifiable evidence of risk.

The awards offer all of us a global opportunity to recognise and acknowledge the advocacy warriors. From researchers to consumers, academics to scientists, individuals who have not only consistently striven to make a difference but have, in the opinion of their peers – resoundingly done so.

Nominations are invited in two categories (although there is considerable overlap). Winners are chosen primarily on the number of votes cast, together with the verified approval of the award panel. Winners of this year's award will be invited to sit on the panel for 2018.

- An advocate for safer nicotine products who has consistency gone 'above and beyond' to spread information, knowledge, enthusiasm and assistance in supporting the rights of others to choose safer alternatives to combustible tobacco.
- An advocate for tobacco harm reduction, who may or may not be a consumer, who utilises their professional status and position by promoting the concept of harm reduction using their background in science, health or academia.

The awards will be presented following the Michael Russell Oration by **Ethan Nadelmann**, the founder and recently retired executive director of the US Drug Policy Alliance. Widely regarded as one of the most outstanding proponents of drug policy reform both in the United States and abroad he is, quite simply, a legend in harm reduction advocacy.

*Judy Gibson
on behalf of the
INNCO Steering Group*

THE ONLY PLACE WHERE SCIENCE AND POLICY MEET

DON'T FORGET

GFN 2018

14-16 June

next year in Warsaw



gfn.net.co

 **KNOWLEDGE**
ACTION CHANGE